S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Lacking counselors, US schools turn to the booming business of online therapy
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal with debt
Alaska Air Group announces it has agreed to buy Hawaiian Airlines in a $1.9 billion deal with debt
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Lacking counselors, US schools turn to the booming business of online therapy
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal with debt
Alaska Air Group announces it has agreed to buy Hawaiian Airlines in a $1.9 billion deal with debt
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Lacking counselors, US schools turn to the booming business of online therapy
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal with debt
Alaska Air Group announces it has agreed to buy Hawaiian Airlines in a $1.9 billion deal with debt
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Lacking counselors, US schools turn to the booming business of online therapy
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal with debt
Alaska Air Group announces it has agreed to buy Hawaiian Airlines in a $1.9 billion deal with debt

Aeterna Zentaris Stock Price, News & Analysis (NASDAQ:AEZS)

$2.08
+0.10 (+5.05%)
(As of 12/1/2023 ET)
Compare
Today's Range
$1.96
$2.08
50-Day Range
$1.42
$2.50
52-Week Range
$1.36
$4.00
Volume
5,869 shs
Average Volume
11,036 shs
Market Capitalization
$10.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Aeterna Zentaris MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
621.2% Upside
$15.00 Price Target
Short Interest
Bearish
0.98% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of Aeterna Zentaris in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.22) to ($3.37) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

652nd out of 957 stocks

Pharmaceutical Preparations Industry

311th out of 443 stocks


AEZS stock logo

About Aeterna Zentaris Stock (NASDAQ:AEZS)

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

AEZS Stock Price History

AEZS Stock News Headlines

AEterna Zentaris Inc AEZS
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Aeterna Zentaris GAAP EPS of -$0.85
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Closing Bell: Aeterna Zentaris Inc down on Monday (AEZS)
Closing Bell: Aeterna Zentaris Inc flat on Tuesday (AEZS)
H.C. Wainwright Keeps Their Buy Rating on Aeterna Zentaris (AEZS)
See More Headlines
Receive AEZS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/03/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/28/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AEZS
Employees
11
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.00
High Stock Price Target
$15.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+621.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-22,730,000.00
Net Margins
-340.56%
Pretax Margin
-340.56%

Debt

Sales & Book Value

Annual Sales
$5.64 million
Book Value
$5.41 per share

Miscellaneous

Free Float
4,851,000
Market Cap
$10.11 million
Optionable
Optionable
Beta
1.63

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Klaus Paulini Ph.D.
    President, CEO & Executive Director
  • Mr. Giuliano La Fratta
    Senior VP of Finance & CFO
  • Dr. Michael Teifel Ph.D.
    Senior VP of Non-Clinical Development & Chief Scientific Officer
  • Dr. Nicola Ammer M.D.
    Chief Medical Officer & Senior VP of Clinical Development
  • Dr. Matthias Gerlach
    Senior Vice President Manufacturing & Supply Chain














AEZS Stock Analysis - Frequently Asked Questions

Should I buy or sell Aeterna Zentaris stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aeterna Zentaris in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AEZS shares.
View AEZS analyst ratings
or view top-rated stocks.

What is Aeterna Zentaris' stock price target for 2024?

1 analysts have issued twelve-month target prices for Aeterna Zentaris' stock. Their AEZS share price targets range from $15.00 to $15.00. On average, they anticipate the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 621.2% from the stock's current price.
View analysts price targets for AEZS
or view top-rated stocks among Wall Street analysts.

How have AEZS shares performed in 2023?

Aeterna Zentaris' stock was trading at $3.18 at the beginning of the year. Since then, AEZS stock has decreased by 34.6% and is now trading at $2.08.
View the best growth stocks for 2023 here
.

When is Aeterna Zentaris' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our AEZS earnings forecast
.

How were Aeterna Zentaris' earnings last quarter?

Aeterna Zentaris Inc. (NASDAQ:AEZS) released its quarterly earnings results on Thursday, November, 9th. The biopharmaceutical company reported ($0.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by $0.24. Aeterna Zentaris had a negative trailing twelve-month return on equity of 49.10% and a negative net margin of 340.56%.

When did Aeterna Zentaris' stock split?

Aeterna Zentaris's stock reverse split on the morning of Thursday, July 21st 2022. The 1-25 reverse split was announced on Thursday, July 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Aeterna Zentaris own?
Who are Aeterna Zentaris' major shareholders?

Aeterna Zentaris' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Aeterna Zentaris?

Shares of AEZS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AEZS) was last updated on 12/3/2023 by MarketBeat.com Staff

My Account -